论文部分内容阅读
安吉宁是日本合成的抗动脉粥样硬化新药,广东省医药工业研究所1972年试制成功。动物毒性试验表明:不同批号之间、国产安吉宁与日本安吉宁之间,小白鼠半数致死量无显著差别。大剂量(0.8克/公斤/天)灌胃7天,两种安吉宁都可引起血清谷丙转氨酶增高;小剂量(0.4克/公斤/天)连续灌胃1月,均不引起谷丙转氨酶增高。为了了解安吉宁有否预防动脉粥样硬化斑形成和降低血脂作用,观察了安吉宁对家兔实验性高脂血症和动脉粥样硬化的影响。实验证明,安吉宁不能防止喂胆固醇引起的高脂血症,没有降血脂作用。主动脉壁总胆固醇、总脂和斑块面积还比对照组高。
Anjining is Japan’s synthetic anti-atherosclerotic new drug, Guangdong Institute of Pharmaceutical Industry trial success in 1972. Animal toxicity test showed that: between different batches, between domestic Anjining and Japan’s Anjining, the mice were not significantly different from the median lethal dose. High-dose (0.8g / kg / day) gavage for 7 days, two kinds of analgesic can cause elevated serum alanine aminotransferase; small dose (0.4g / kg / day) continuous gavage in January, did not cause elevated alanine aminotransferase . In order to understand whether Anjining prevent atherosclerotic plaque formation and reduce blood lipids, observed Angin on rabbit experimental hyperlipidemia and atherosclerosis. Experiments show that Anjining can not prevent hyperlipidemia caused by cholesterol-fed, there is no hypolipidemic effect. Aortic wall total cholesterol, total fat and plaque area is also higher than the control group.